European medicines regulator recommends approval for Novo's Wegovy pill

The European ​Medicines Agency recommended ‌approval for Novo ​Nordisk's ​weight-loss pill Wegovy, ⁠the ​regulator said ​on Friday, clearing its path ​to ​become the first ‌oral ⁠weight loss drug in ​Europe, ​ahead ⁠of U.S. ​rival ​Eli ⁠Lilly.

Reuters • 20 hours ago

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, ​a top executive said, as the Danish drugmaker looks to regain momentum in ‌the booming obesity drugs market.

Reuters • 18 hours ago

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction.

GlobeNewsWire • 18 hours ago

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. Wegovy® 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme.

GlobeNewsWire • 13 hours ago

European Regulator Backs Novo Nordisk's Wegovy Weight-Loss Pill

The recommendation paves the way for it to become the first tablet approved to treat obesity in the European Union.

WSJ • 18 hours ago

Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say

Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U.S. doctors.

Reuters • May 21, 2026

Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank

Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Emmanuel Papadakis said the key takeaway was that Novo is cautiously optimistic its cagrisema RD11 obesity study will yield a better result than the earlier RD4 trial, which disappointed markets when data was released.

Proactive Investors • May 20, 2026

Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant

I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer to Eli Lilly than market sentiment suggests. Despite pricing and clinical setbacks, the company's stable revenue outlook and potential P/E re-rating support mid-teens annualized returns through 2030.

Seeking Alpha • May 20, 2026

Best Weight Loss Drug Stocks to Buy in 2026

Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.

The Motley Fool • May 21, 2026

US Supreme Court rebuffs pharma challenge to Biden-era drug price

The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan ​to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that drugmakers argued ‌illegally forces them to accept steep discounts and jeopardizes innovation.

Reuters • May 18, 2026